Table 2.
Unadjusted fracture rates overall and in high-risk women due to older age or comorbidity/medication
| Full study cohorts | Subgroups with high-risk of fracture at baseline | |||
|---|---|---|---|---|
| Aged ≥ 65 years |
Aged ≥ 70 years |
High-risk due to comorbidity/medicationa |
||
| Women, N (women-years of observationb) | ||||
| GR risedronate | 1080 (3204) | 575 (1871) | 420 (1394) | 799 (2392) |
| IR risedronate | 1080 (3506) | 586 (2086) | 400 (1428) | 758 (2437) |
| Alendronate | 14,040 (44,566) | 8437 (28,635) | 6194 (21,097) | 10,057 (31,988) |
| Fractures, N (unadjusted rate per 1000 women-years) | ||||
| Any fracture | ||||
| GR risedronate | 162 (50.6) | 109 (58.3) | 94 (67.4) | 143 (59.8) |
| IR risedronate | 227 (64.8) | 184 (88.2) | 139 (97.3) | 194 (79.6) |
| Alendronate | 2977 (66.8) | 2498 (87.2) | 2142 (101.5 | 2568 (80.3) |
| Hip | ||||
| GR risedronate | 45 (14.0) | 35 (18.7) | 31 (22.2) | 40 (16.7) |
| IR risedronate | 53 (15.1) | 43 (20.6) | 42 (29.4) | 50 (20.5) |
| Alendronate | 835 (18.7) | 746 (26.1) | 658 (31.2) | 744 (23.3) |
| Pelvis | ||||
| GR risedronate | 11 (3.4) | 11 (5.9) | 6 (4.3) | 10 (4.2) |
| IR risedronate | 24 (6.9) | 21 (10.1) | 18 (12.6) | 23 (9.4) |
| Alendronate | 309 (6.9) | 281 (9.8) | 248 (11.8) | 274 (8.6) |
| Spine | ||||
| GR risedronate | 60 (18.7) | 46 (24.6) | 43 (30.9) | 55 (23.0) |
| IR risedronate | 96 (27.4) | 80 (38.4) | 59 (41.3) | 81 (33.2) |
| Alendronate | 1,087 (24.4) | 949 (33.1) | 840 (39.8) | 968 (30.3) |
| Wrist/arm | ||||
| GR risedronate | 58 (18.1) | 27 (14.4) | 20 (14.4) | 49 (20.5) |
| IR risedronate | 66 (18.8) | 51 (24.5) | 31 (21.7) | 52 (21.3) |
| Alendronate | 924 (20.7) | 684 (23.9) | 527 (25.9) | 740 (23.1) |
GR gastro-resistant, IR immediate release.
aWomen with a high baseline risk of fracture due to comorbidities and/or medications were identified based on the presence of ≥ 1 baseline diagnosis for heart failure, chronic pulmonary disease, dementia, depression, diabetes, Parkinson’s disease, or osteoporotic fracture, and/or ≥ 1 baseline dispensing of a treatment increasing the risk of fracture (e.g., systemic corticosteroids, sedatives, proton pump inhibitors), or loop diuretics.
bFractures were measured over an observation period measured from the index date to the earliest of data cut-off date, end of insurance eligibility, or initiation of an oral bisphosphonate other than the index treatment